Trials

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Cancer type: Skin cancer

Phase: II

Principal Investigator: Bratland ├ůse

Country: NO

Keywords: Norway, Oslo, MK3475-629, Pembrolizumab, Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03284424?term=MK-3475-629&recrs=ab&rank=1